Spasticity Lab Report

1.1. INTRODUCTION
Spasticity is a condition in which certain muscles are continuously contracted. This contraction causes stiffness or tightness of the muscles and can interfere with normal movement and speech. Spasticity is usually caused by damage to the portion of the brain or spinal cord that controls voluntary movement. The damage causes a change in the balance of signals between the nervous system and the muscles. This imbalance leads to increased activity in the muscles. Spasticity negatively affects muscles and joints of the extremities, and is particularly harmful to growing children.
1.2. PREVALENCE AND INCIDENCE
 Spasticity affects more than an estimated 12 million people worldwide.

1.3. OTHER CONDITIONS THAT MAY CAUSE SPASTICITY INCLUDE[2]
 Traumatic brain injury (TBI)
 Spinal cord injury (SCI)
 Brain damage due to a lack of oxygen
 Stroke
 Encephalitis
 Meningitis

Drug
2. Oil
3. Surfactant
4. Co-surfactant
5. Co-solvent
6. Antioxidant[9]

1.8 Hypothesis
• It is hypothesized that smedds by lymphatic targetting of the drug will avoid first pass metabolism of the drug and enhance its oral bioavailability and thereby reduce dose and dosing frequency which ultimately will reduce the toxicity profile. It will also reduce the food dependent dissolution and thereby enhance patient compliance.
• It is hypothesized that gastroretentive cpop will provide sustained drug delivery (zero order ),enhace site specific targetting to enhance bioavailability and decrease dose and dosage frequency, ultimately decrease the toxicity profile and increase patient compliance.

1.9 AIMS AND OBJECTIVE
The aim of the study is to formulate-
1. Smedds tablet and capsule to enhance its oral bioavalability by lymphatic targetting.
2. Floating CPOP to achieve zero order controlled release to reduce its toxicity profile and its prolonged activity.

1.10 PLAN OF WORK(FOR CPOP AND SMEDDS)
1. Literature Review
2. Analytical Method
3. Preformulation